TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive NCI To Pay 34 Percent Of Grants, At 155 Payline; $100 Million for Centers to Fund All Core Grants January 29, 1988